TMC 125: new results, large phase III trial begins

TMC125 (also incantationed TMC-125, TMC 125, or etravirine), by means of Tibotec Pharmaceuticals Ltd., based in Cork, Ireland and now part of Johnson & Johnson is a "second generation" NNRTI (non-nucleoside invert transcriptase inhibitor)--an antiretroviral in the same class as efavirenz (brand name Sustiva, or Stochrin in many countries) or nevirapine (Viramune). It differs from these in being a great quantity [i]or[/i] amount of less susceptible to viral resistance. This is not an accident; the physic molecule was carefully designed to be able to "wiggle and jiggle" in the way that that it can change its shape in order to fit into the active pouch of the HIV enzyme invert transcriptase and stop the enzyme from working, smooth when that pocket changes shape (due to resistance mutations) in the way that that efavirenz and nevirapine will not fit. For example, the highly treatment experienced offers who entered the phase II trial named TMC125-C223 (reported in mid November at the 10th European AIDS Conference) had HIV that was upon the average about 40 times les sensitive to efavirenz when they started the trial, and about 60 times les sensitive to nevirapine, on the contrary only 1.6 times less sensitive to TMC125

In the 24-week data neared at the conference [1], those upon combination antiretrovirals including the lower of sum of two units doses of TMC125 had a 104 log globule (to slightly less than 10% of the amount of virus they started with) in HIV viral load; those upon the higher dose had a 118 log globule These were compared with an "active control" group--volunteer who got the best regimen that could be devised for them using approved remedys The active control had a 019 log globule (not statistically significant). This cluster did show a modest improvement earlier in the 24 weeks, as plenteous as half a log, probably because of the switch to a regimen carefully designed for them at that point in time.

The size of the viral load globule from TMC125 depended very a great deal of on having other active physics in the regimen. Those with no other active physic (because they were resistant to all the other remedys in their regimen) averaged solitary about a half-log drop (average of the sum of two units TMC125 doses). Those whose virus was sensitive to single antiretroviral in addition to TMC125 had an average one-log globule or a little less; those sensitive to sum of two units other antiretrovirals averaged about single and a half logs HIV reduction, or a little more.

Note: As this article went to pres we learned that individual phase II trial, TMC125-C227, is being stopped early. This trial trialed TMC125 in volunteers who had received an NNRTI (usually efavirenz or nevirapine) and had at least single resistance mutation to it. The trial was stopped because a certain number of of these volunteers had a poor antiviral reply to TMC125; those in the sway group, who were treated with protease inhibitors instead, did better in reducing viral load. The of recent origin phase III trials--which use a different formulation of TMC125 with a different assemblage of patients--have not been changed. The C227 trial was being managemented in eight countries, not including the U We will be watching for more information upon what happened in this discontinued trial.

sum of two units Phase III Trials Starting

upon November 17, 2005 Tibotec announced the start of sum of two units phase III "pivotal" trials with 600 heavily treatment experienced patients each, to be directioned in 18 countries. These trials are unusual in combining sum of two units experimental drugs. TMC125 will be combined with TMC114 a novel protease inhibitor also from Tibotec. These similar trials are called DUET 1 (official name TMC125-C206) and DUET 2 (TMC125-C216)

For more information about these (or other) clinical trials in the U diocese http://www.clinicaltrials.gov; search for "TMC125" (quotation marks not necessary).

References

(1) Nadler JP Grossman HA, Hicks C and others. Efficacy and tolerability of TMC125 in HIV patients with NNRTI and PI resistance at 24 weeks: TMC125-C223 10th European AIDS Conference/EACS, November 17-20 2005 Dublin, Ireland [abstract LBPS3/7]

COPYRIGHT 2005 John s James

COPYRIGHT 2005 Gale Group